Related Experiment Videos
Immunologic escape and angiogenesis in human malignant melanoma
Pedro Redondo1, Ignacio Sánchez-Carpintero, Ana Bauzá
1Department of Dermatology, University Clinic of Navarra, School of Medicine, Pamplona, Spain. predondo@unav.es
Journal of the American Academy of Dermatology
|August 2, 2003
Summary
Vascular Endothelial Growth Factor (VEGF) expression in melanoma may indicate a poor prognosis. Both proangiogenic and immunosuppressive cytokines are elevated in metastatic melanoma, with an inverse relationship observed between VEGF and IL-10 levels.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Melanoma utilizes immunosuppressive and angiogenic cytokines for immune evasion.
- Understanding these cytokine profiles is crucial for developing targeted therapies.
Purpose of the Study:
- To assess the expression and plasma levels of key angiogenic and immunosuppressive cytokines in melanoma patients.
- To correlate these levels with melanoma stage and patient outcomes.
Main Methods:
- Immunohistochemistry was used to evaluate VEGF and bFGF expression in primary melanomas.
- Plasma levels of VEGF, bFGF, IL-10, and TGF-β2 were measured in melanoma patients and healthy controls.
- Patient cohorts were stratified by melanoma stage (I-IV).
Main Results:
- VEGF and bFGF were frequently expressed in primary melanomas.
- Elevated plasma levels of VEGF, bFGF, and IL-10 were observed in advanced melanoma stages (III and IV) compared to controls.
- A significant inverse correlation was found between plasma VEGF and IL-10 levels in metastatic melanoma patients.
Conclusions:
- VEGF expression in melanomas with Breslow depth of 1.5-3.0 mm is a potential unfavorable prognostic indicator.
- Increased levels of proangiogenic (VEGF, bFGF) and immunosuppressive (IL-10, TGF-β2) cytokines are characteristic of metastatic melanoma.
- The in vivo inverse relationship between IL-10 and VEGF in metastatic melanoma warrants further investigation.